DNAJC6 Gene PARK19 Parkinson, juvenile-onset NGS Genetic Test
Short Name: DNAJC6 PARK19 NGS Test
Also known as: DNAJC6 Gene Mutation Analysis, PARK19 Genetic Test, DNAJC6 Parkinson's Gene Panel, Juvenile Parkinson DNAJC6 Sequencing, DNAJC6 NGS Sequencing Test
DNAJC6 Gene PARK19 Parkinson, juvenile-onset NGS Genetic Test test available at DNA Labs India for ₹20,000. Uses Next Generation Sequencing (NGS) on Blood or Extracted DNA or One Drop Blood on FTA Card samples. Results in Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent cases may be prioritised upon request. Results are accessible through the DNA Labs India online portal, and notifications are sent via email and WhatsApp.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last reviewed: September 7, 2026
Overview
The primary purpose of the DNAJC6 Gene PARK19 NGS Genetic Test is to identify pathogenic or likely pathogenic mutations in the DNAJC6 gene that are associated with juvenile-onset Parkinson's disease. This test is used for: confirming a clinical diagnosis of PARK19-associated juvenile-onset Parkinson's disease in symptomatic individuals; identifying causative genetic variants to guide personalised treatment approaches; enabling carrier testing for family members of affected individuals; facilitating informed genetic counselling regarding recurrence risks and family planning; supporting differential diagnosis of juvenile-onset movement disorders; and contributing to research and clinical understanding of genetic forms of Parkinson's disease. This test does not diagnose all forms of Parkinson's disease and should be interpreted in the context of clinical findings and family history.
- Test Code
- 1780
- CPT Code
- 81479
- ICD Code
- G20; G11.9
- Price
- ₹20,000
- Sample Type
- Blood or Extracted DNA or One Drop Blood on FTA Card
- Result Time
- Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent cases may be prioritised upon request. Results are accessible through the DNA Labs India online portal, and notifications are sent via email and WhatsApp.
- Fasting Required
- No
- Method
- Next Generation Sequencing (NGS)
Sample Collection
No special preparation or fasting is required. A genetic counselling session is recommended prior to sample collection to obtain informed consent, document detailed clinical history, and prepare a pedigree chart of affected family members.
Method: Venipuncture
Laboratory Analysis
A qualified phlebotomist will collect approximately 3 mL of venous blood in an EDTA vacutainer under aseptic conditions. Alternatively, one drop of blood may be collected on an FTA card. If extracted DNA is available, it may be submitted directly.
Report Delivery
The sample will be labelled, stored at ambient room temperature, and transported to the laboratory under standard conditions. Results will be available within 3 to 4 weeks and delivered via the online portal, email, or WhatsApp.
Timeline: Results are typically available within 3 to 4 weeks from the date of sample receipt at the laboratory. Urgent cases may be prioritised upon request. Results are accessible through the DNA Labs India online portal, and notifications are sent via email and WhatsApp.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of the DNAJC6 Gene PARK19 NGS Genetic Test is to identify pathogenic or likely pathogenic mutations in the DNAJC6 gene that are associated with juvenile-onset Parkinson's disease. This test is used for: confirming a clinical diagnosis of PARK19-associated juvenile-onset Parkinson's disease in symptomatic individuals; identifying causative genetic variants to guide personalised treatment approaches; enabling carrier testing for family members of affected individuals; facilitating informed genetic counselling regarding recurrence risks and family planning; supporting differential diagnosis of juvenile-onset movement disorders; and contributing to research and clinical understanding of genetic forms of Parkinson's disease. This test does not diagnose all forms of Parkinson's disease and should be interpreted in the context of clinical findings and family history.
How to Prepare
- Ensure a genetic counselling session has been completed prior to sample collection
- Provide a detailed clinical history and family pedigree at the time of booking
- Blood sample (3 mL) should be collected in an EDTA (lavender top) vacutainer
- Alternatively, one drop of blood can be collected on an FTA card
- Label the sample correctly with patient name, date of birth, and unique identifier
- Store and transport the sample at ambient room temperature (15-30°C)
- Avoid freezing the blood sample
- If using extracted DNA, ensure concentration is at least 20 ng/µL with A260/A280 ratio of 1.7-2.0
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"Juvenile-onset Parkinson's disease linked to DNAJC6 mutations is rare but clinically significant. Genetic testing with NGS allows precise identification of pathogenic variants, enabling early intervention, targeted treatment planning, and informed genetic counselling for affected families. I recommend this test for any patient presenting with parkinsonian symptoms before age 20, especially with a positive family history."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Haemolysed, clotted, or insufficient sample volume
- Improperly labelled or unlabelled samples
- Samples collected in incorrect anticoagulant (e.g., heparin tubes)
- Samples received without completed requisition form or clinical history
- Contaminated or leaking sample containers
- Blood sample older than 5 days at ambient temperature
Understanding Your Results
No known pathogenic or likely pathogenic mutation was identified in the DNAJC6 gene. This result reduces the likelihood that the patient's symptoms are caused by DNAJC6-related PARK19 but does not exclude other genetic or non-genetic causes of juvenile-onset Parkinson's disease. Clinical correlation and further genetic testing may be considered.
Two copies of a pathogenic variant in the DNAJC6 gene were identified, consistent with autosomal recessive inheritance. This finding supports a molecular diagnosis of PARK19-associated juvenile-onset Parkinson's disease. Genetic counselling is recommended for the patient and family members.
Two different pathogenic variants were identified on separate alleles of the DNAJC6 gene, consistent with compound heterozygosity and autosomal recessive PARK19. Carrier testing of parents is recommended to confirm inheritance. Genetic counselling is advised.
Only one pathogenic variant was identified in the DNAJC6 gene. The individual is a carrier for PARK19. If clinical symptoms are present, the second variant may be missed by this method, or the condition may have a different genetic or non-genetic cause. Additional testing or evaluation may be warranted.
A variant in the DNAJC6 gene was identified that cannot currently be classified as pathogenic or benign. This result is not diagnostic. Clinical correlation, family segregation studies, and periodic re-evaluation as new data become available are recommended.
Consult your neurologist or clinical geneticist if: you or your child develops tremors, stiffness, slowness of movement, or balance problems before the age of 20; genetic test results identify a pathogenic variant or a variant of uncertain significance; you have a family history of juvenile-onset Parkinson's disease and wish to discuss carrier testing or family planning options; or if symptoms progress or new symptoms develop after a negative test result, as additional genetic or clinical evaluation may be needed.
Limitations
- ⚠This test analyses only the DNAJC6 gene and does not screen for mutations in other Parkinson's disease-associated genes (e.g., SNCA, LRRK2, PARK2, PINK1, PARK7)
- ⚠Deep intronic mutations and large structural rearrangements beyond the resolution of NGS may not be detected
- ⚠Variants of Uncertain Significance (VUS) may be identified that cannot be definitively classified as pathogenic or benign at the time of reporting
- ⚠A negative result does not exclude the diagnosis of juvenile-onset Parkinson's disease as it may be caused by mutations in other genes or non-genetic factors
- ⚠This test is not validated for prenatal diagnosis or preimplantation genetic diagnosis without separate validation
- ⚠Somatic mosaicism at low allele frequencies may not be detected
Risks & Considerations
- ●Minor bruising or discomfort at the blood draw site
- ●Very slight risk of infection at the needle insertion site (standard phlebotomy risk)
- ●Potential psychological impact of receiving genetic results, particularly pathogenic findings
- ●Risk of anxiety or distress related to variants of uncertain significance (VUS)
- ●Potential implications for insurance and employment (genetic non-discrimination protections vary by jurisdiction)
Interfering Factors
- ●Recent blood transfusion (within 4 weeks) may affect DNA quality and results
- ●Degraded or insufficient DNA sample quality may necessitate recollection
- ●Haemolysed samples may interfere with DNA extraction efficiency
- ●Contamination during sample collection or processing may impact sequencing accuracy
Compare With Similar Tests
| Test | DNAJC6 Gene PARK19 Parkinson, juvenile-onset NGS Genetic Test | LRRK2 Gene Test | PARK2 (Parkin) Gene Test | Comprehensive Parkinson's Gene Panel | SNCA Gene Test | PINK1 Gene Test |
|---|---|---|---|---|---|---|
| Comparison | DNAJC6 Gene PARK19 Parkinson, juvenile-onset NGS Genetic Test | LRRK2 gene mutations are the most common cause of autosomal dominant late-onset Parkinson's disease. Unlike DNAJC6 (PARK19), which causes autosomal recessive juvenile-onset Parkinson's, LRRK2 testing is typically indicated for adult-onset familial Parkinson's disease. | PARK2 encodes parkin and is the most common cause of autosomal recessive juvenile-onset Parkinson's disease. DNAJC6 (PARK19) is rarer. Both follow autosomal recessive inheritance, but PARK2 is more frequently implicated in juvenile-onset cases. | A comprehensive panel tests multiple genes (SNCA, LRRK2, PARK2, PINK1, PARK7, DNAJC6, etc.) simultaneously. The DNAJC6 single-gene test is more targeted and cost-effective when clinical suspicion specifically points to PARK19. | SNCA gene mutations cause autosomal dominant Parkinson's disease (PARK1/PARK4). Unlike DNAJC6, SNCA mutations are typically associated with late-onset disease with autosomal dominant inheritance, making it clinically distinct from PARK19. | PINK1 (PARK6) is another gene associated with autosomal recessive early-onset and juvenile-onset Parkinson's disease. Clinical features overlap with DNAJC6-related PARK19, and both tests may be considered in the diagnostic workup of juvenile-onset cases. |
Frequently Asked Questions
What is the DNAJC6 Gene PARK19 NGS Genetic Test?
Who should undergo the DNAJC6 Gene PARK19 Genetic Test?
What is the cost of the DNAJC6 Gene PARK19 NGS Genetic Test at DNA Labs India?
What sample is required for this test?
Is fasting required before the DNAJC6 Gene test?
How long does it take to receive the test results?
Is home sample collection available for this test?
What does a negative test result mean?
What is the difference between DNAJC6 (PARK19) and other Parkinson's disease genes?
Can this test be used for prenatal diagnosis or carrier screening?
Is genetic counselling mandatory before taking this test?
Are there any risks associated with the DNAJC6 Gene PARK19 Genetic Test?
Related Tests
Angelman Syndrome Test
₹10,000Duchenne / Becker Muscular Dystrophy (DMD / BMD) Gene Mutation Test
₹14,000Episodic Ataxia Type 1 Hotspot Test
₹11,500Episodic Ataxia Comprehensive Profile Hotspot Test
₹16,000Megalencephalic Leukoencephalopathy with Subcortical Cysts Van Der Knaap and Nalband MLC Gene Hotspot Mutation Test
₹7,500Analyzer 18 SMA 18 Test Panel
₹1,755Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.